Receive Our Newsletter

FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia B



Novo Nordisk recently announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. Novo Nordisk expects to launch REBINYN® in the U.S. in the first half of 2018.

For more info on REBINYN, read the full press release here.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community